IP Library Granted Patent US 9,820,953
Granted Patent B2
US 9,820,953 · App. 15/360,279 · Granted Nov 21, 2017

Compositions of bioactive fulvate fractions and uses thereof

Inventors: Gary W. Black (Pottstown, PA); Jane Christensen (Phoenix, AZ); Farhan Taghizadeh (Albuquerque, NM)
Assignee: Omni Bioceutical Innovations, Inc.
A61K31/194A61K9/0014A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,820,953
App. No.
15/360,279
Granted
Nov 21, 2017
Kind
B2
Abstract

Compositions with fulvate fractions alone or in combination with growth factors, bioactive fragmented peptides, or combinations thereof are disclosed herein. Also disclosed are methods of using said compositions for the catalyzing cellular regeneration, including the healing, treatment, or prevention of skin disorders. Also disclosed are methods for extracting, isolating, and purifying fulvate fractions for use in the manufacture of said compositions.

Claims (23)

1. A composition for treatment of a subject in need of cell regeneration comprising an isolated fulvate fraction having a molecular formula of C 12 H 16 O 9 and having an average molecular weight ranging from 80 to 350 Da, as measured by vapor pressure osmometry, the composition further comprising a growth factor or a bioactive peptide, and wherein the fulvate fraction is isolated by the following process:

providing an aqueous slurry comprising humified organic matter;

applying the aqueous slurry to high pressure column fractionation to obtain fractionated samples;

applying the fractionated samples to molecular sieving; and

isolating a fulvate fraction.

2. The composition of claim 1 , wherein the isolated fulvate fraction has an average molecular weight ranging from 300 to 320 Da, as measured by vapor pressure osmometry.

3. The composition of claim 1 , wherein the isolated fulvate fraction has an average molecular weight of about 308.24 Da, as measured by vapor pressure osmometry.

4. The composition of claim 1 , wherein the isolated fulvate fraction has an average molecular weight of 309 Da, as measured by vapor pressure osmometry.

5. The composition of claim 1 , wherein the composition is formulated as a topical composition.

6. The composition of claim 1 , wherein the growth factor or the bioactive peptide is a growth factor.

7. The composition of claim 6 , wherein the growth factor is EGF, PDGF, FGF, TGF-α, TGF-β, NGF, EPO, IGF-I, IGF-II, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IFN-α, IFN-β, IFN-γ, TNFα, TNF-β, GM-CSF, M-CSF, VEGF, HGF, KGF, or combinations thereof.

8. The composition of claim 1 , wherein the growth factor or the bioactive peptide is a bioactive peptide.

9. The composition of claim 8 , wherein the bioactive peptide is a tigerinin-based peptide.

10. The composition of claim 8 , wherein the bioactive peptide is Syndermin palmitoyl tripeptide-1 amide, Synepin palmitoyl sh-tripeptide-3 amide, Binterin palmitoyl sh-tripeptide-4 amide, Winhibin palmitoyl sh-tripeptide-53 amide, Adiponin palmitoyl sh-tripeptide-1 amide, or combinations thereof.

11. The composition of claim 10 , wherein the bioactive peptide is Syndermin palmitoyl tripeptide-1 amide.

12. The composition of claim 10 , wherein the bioactive peptide is Synepin palmitoyl sh-tripeptide-3 amide.

13. The composition of claim 10 , wherein the bioactive peptide is Binterin palmitoyl sh-tripeptide-4 amide.

14. The composition of claim 10 , wherein the bioactive peptide is Winhibin palmitoyl sh-tripeptide-53 amide.

15. The composition of claim 10 , wherein the bioactive peptide is Adiponin palmitoyl sh-tripeptide-1 amide.

16. The composition of claim 1 , wherein the composition is formulated as a transdermal composition.

17. The composition of claim 1 , wherein the composition is formulated as a nasal composition.

18. The composition of claim 1 , wherein the composition is formulated as a sublingual composition.

19. The composition of claim 1 , wherein the composition is formulated as an injectable composition.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Dec 20, 2018
From: EDGE SYSTEMS LLC
To: OMNI BIOCEUTICAL INNOVATIONS, INC.
Reel/Frame 047836/0720 →
LIEN Recorded Sep 13, 2018
From: OMNI BIOCEUTICAL INNOVATIONS, INC.
To: EDGE SYSTEMS LLC
Reel/Frame 046867/0092 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2017
From: BLACK, GARY W.; CHRISTENSEN, JANE; TAGHIZADEH, FARHAN
To: OMNI BIOCEUTICAL INNOVATIONS, INC.
Reel/Frame 041684/0238 →
Continuity (2)
Provisional Application 62300541 · Feb 26, 2016
Related Publication 20170246132A1 · Aug 31, 2017